Management of Severe Mitral Stenosis

Initial Assessment and Etiology Determination

• The European Society of Cardiology recommends distinguishing rheumatic mitral stenosis (RMS) from degenerative mitral stenosis (DMS) as interventions differ fundamentally between these etiologies 3
• Rheumatic MS is characterized by commissural fusion, amenable to PMBC, according to the European Heart Journal 3
• Degenerative MS lacks commissural fusion, making PMBC ineffective, as stated in the European Heart Journal 3

Medical Management

• The American College of Cardiology recommends medical therapy, including diuretics for pulmonary congestion or peripheral edema, for symptom relief in patients with severe mitral stenosis 1, 2, 4
• Beta-blockers or rate-limiting calcium channel blockers are recommended for heart rate control, particularly crucial in atrial fibrillation to prolong diastolic filling time, according to Praxis Medical Insights 1, 2
• Digoxin is specifically recommended for heart rate control in patients with atrial fibrillation, as stated in Praxis Medical Insights 1, 2
• Anticoagulation with vitamin K antagonists (target INR 2-3) is mandatory in specific situations, including history of systemic embolism, atrial fibrillation, dense spontaneous contrast in left atrium on echocardiography, and enlarged left atrium, according to Praxis Medical Insights 1, 2, 4

Intervention Indications

• PMBC is indicated for all symptomatic patients with severe MS (valve area ≤1.5 cm²) and favorable valve morphology, as recommended by Praxis Medical Insights 1, 2
• The European Society of Cardiology recommends intervention in asymptomatic patients with pulmonary artery systolic pressure >50 mmHg, new-onset atrial fibrillation, or high thromboembolic risk, according to Praxis Medical Insights 1, 2

Special Populations

• PMBC can be performed relatively safely in symptomatic patients (NYHA III-IV) despite medical therapy during pregnancy, as stated in the European Heart Journal 3
• Mitral valve surgery carries significant risk to mother and fetus, reserved only when mother's life is at risk, according to the European Heart Journal 3

Monitoring After Intervention

• Post-PMBC parameters determining long-term outcomes include mitral valve area achieved, residual mitral regurgitation severity, mean transmitral gradient, and pulmonary artery pressure, as stated in Praxis Medical Insights 1, 2
• The European Society of Cardiology recommends follow-up for asymptomatic severe MS not yet intervened upon every 2-3 years, while the American College of Cardiology/American Heart Association recommends every 3-5 years, according to Praxis Medical Insights 1, 2